Overview
Assertio Q3 adjusted EPS beats analyst expectations, driven by Rolvedon sales
Adjusted EBITDA for Q3 beats consensus, reflecting strong operational performance
Company narrows FY2025 sales and EBITDA guidance
Outlook
Assertio narrows FY2025 net product sales guidance to $110-112 mln
Company updates FY2025 adjusted EBITDA guidance to $14-16 mln
Assertio cites Rolvedon pull-forward for updated 2025 guidance
Result Drivers
ROLVEDON SALES - Rolvedon net product sales increased significantly to $38.6 mln, driven by both normal demand and large distributor purchases for future supply
INTEGRATION EFFORTS - Co advanced integration efforts to consolidate operations under Assertio Specialty Pharmaceuticals, aiming for greater efficiency and cost savings
INDOCIN SALES DECLINE - Indocin sales fell to $4.8 mln due to expected impacts from generic competition
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Adjusted EPS | Beat | $0.18 | -$0.09 (4 Analysts) |
Q3 EPS | $0.11 | ||
Q3 Net Income | $11.40 mln | ||
Q3 Adjusted EBITDA | Beat | $20.90 mln | $3.70 mln (3 Analysts) |
Q3 Income From Operations | $11.48 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Assertio Holdings Inc is $3.00, about 74.7% above its November 7 closing price of $0.76
Press Release: ID:nBwWBCr4a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)